CANNAPHARMARX
Leading the way in Endocannabinoid System research and innovation within the healthcare community
Leading the way in Endocannabinoid System research and innovation within the healthcare community
CannaPharmaRx is a leading player in the healthcare community, focusing on Endocannabinoid System (ECS) research and development. Since its establishment in 1998, the company has been making waves in the Biopharma, Health Care, and Pharmaceutical industries. Their most recent milestone is the $4.00M Post-IPO Equity investment, which took place on 12 December 2020, with funds coming from Granite Capital Partners. With a dedication to innovation and research, CannaPharmaRx continues to pave the way in ECS research, aiming to make significant contributions to the healthcare community.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $4.00M | 1 |
|
12 Dec 2020 |
| Post-IPO Equity | $3.00M | 1 |
|
09 Aug 2020 |
| Post-IPO Equity | $804.50K | - | 10 Aug 2015 | |
| Post-IPO Equity | $1.40M | - | 12 May 2014 |
No recent news or press coverage available for CANNAPHARMARX.
We care about your data, and we'd love to use cookies make your experience better.